Dr. Westbrook on 3-Year Follow-Up Data of the KRISTINE Trial in HER2+ Breast Cancer

Video

Kelly E. Westbrook, MD, discusses the 3-year follow-up data on the KRISTINE trial in stage II or III HER2-positive breast cancer.

Kelly E. Westbrook, MD, assistant professor, Duke University School of Medicine, discusses the 3-year follow-up data on the KRISTINE trial in stage II or III HER2-positive breast cancer.

The disease-free survival from the time of surgery for trastuzumab (Herceptin), pertuzumab (Perjeta), docetaxel, and carboplatin (TCHP) versus ado-trastuzumab emtansine (T-DM1; Kadcyla) plus pertuzumab was not significantly different, explains Westbrook. However, event-free survival at 3 years was higher for the TCHP arm at 94.2% versus 85.3% in the T-DM1 plus pertuzumab arm. The Kaplan-Meier curve shows the failure of the T-DM1 plus pertuzumab regimen in the neoadjuvant setting, says Westbrook.

Researchers hypothesize the reason for the T-DM1 plus pertuzumab failure is related to tumor heterogeneity, according to Westbrook. Patients who get T-DM1 plus pertuzumab are only getting therapy that is targeted at the HER2 receptor if there are cells not significantly HER2 overexpressing. There is no chemotherapy backbone in that regimen to offer for treatment of that portion of the tumor, Westbrook concludes.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD